

The applications of circulating cell-free DNA for oral squamous cell carcinoma patients as non-invasive diagnostics of structural variants, fusions and oncoviruses

Mahua Bhattacharya^{1,†}, Dan Yaniv^{2,†}, Eyal Yosef², Sharon Tzelnick³, Rajesh Detroja¹, Dylan P. D'Souza¹, Gidi Baum¹, Aviram Mizrachi², Gideon Bachar² and Milana Frenkel Morgenstern^{1,4*}

¹ Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel

² Rabin Medical Research Centre, Tel Aviv, Israel

³ Division of Head and Neck Surgery, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada

⁴ **Current address:** Scojen Institute of Synthetic Biology, Reichman University, Herzliya, Israel

† Authors contributed equally

* Corresponding author: milana.morgenstern@runi.ac.il

Abstract

Circulating cell-free DNA (cfDNA) has been widely used as a prognostic marker for different cancers. In this study, we used cfDNA from oral squamous cell carcinoma (OSCC) patients to study various correlation factors that could improve the disease early-stage diagnostics and/or prognosis. We found that OSCC patient cfDNA concentration can serve as an indicator of tumor stage, malignancy, and survival prognosis. Deep genome sequencing of cfDNA revealed genomic alterations, such as copy number variations, fusion gene identification, and viral integrations. Copy number variation analysis suggested correlation with amplification and deletion in chromosome 1 at loci 1q, 2q, 3p, 3q and 8q22. Moreover, at these loci, amplification of *TP53*, *PIK3CA* and other genes related to keratinization in OSCC patients were observed. In addition, we identified the novel fusion gene, *TRMO-TRNT1* 'chimera', in seven high-grade tumor samples. The parental genes of this chimera, *TRMO* and *TRNT1*, are known to play roles in tRNA modification and DNA repair, respectively. Therefore, our study indicates that liquid biopsy may thus serve as a sensitive tool to study OSCC patient genomic alterations by exploring cfDNA circulating in the plasma, by means of an easy-to-use blood test. Finally, we detected integrations of human papilloma virus, simian virus, and enterovirus in the OSCC samples, that may point to the origins of OSCC.

Introduction

Oral squamous cell carcinoma (OSCC) considered a part of head and neck squamous cell carcinoma (HNSCC)¹, affects the oral and buccal regions, including the gums, the floor of the mouth, and the tongue, palate, and lips². OSCC is the 16th most common form of cancer and the 15th highest contributor to morbidity rates due to cancer³. Oral cancer is mostly associated with lifestyle, being linked to smoking and drinking, although some authors suggest that pre-disposition to human papilloma virus (HPV) is also linked to OSCC³⁻⁶. While early diagnosis can help prevent metastasis and progression, OSCC often goes undiagnosed until a late stage when symptoms are observed, making radiotherapy and chemotherapy less effective⁷.

The discovery of non-invasive methods, like liquid biopsy, has led to progress in cancer diagnostics⁸, specifically, to improved diagnosis of lung, blood, colorectal and cervical cancers, among others. At the same time, liquid biopsy analysis of cell-free DNA (cfDNA) in plasma, saliva and urine has helped determine the survival prognosis⁹⁻¹³ of patients. CfDNA fragments appear in the plasma because of cellular apoptosis or necrosis. The amount of released cfDNA correlates with tumor burden and metastasis¹⁴⁻¹⁹. The cfDNA analyses have been already conducted on HNSCC patients, specifically, on OSCC patients^{8,20,21}. Human papilloma virus (HPV) is one of the major causes of HNSCC, with a significantly mutated *HPV* gene being a major cause of HNSCC²²⁻²⁴. The presence of HPV and other pathogens as revealed by cfDNA analyses of OSCC patients has made diagnosis and prognosis at early stages possible^{1,14,25-30}.

Previous studies reported the presence of a second virus, herpes simplex virus (HSV), in HNSCC and other squamous cell carcinomas, like cervical cancer, and correlated the presence of HPV and HSV with oncogenesis of these cancers. Since OSCC is one of the most common head and neck cancers, we were interested in analyzing cfDNA from patients belonging to an Israeli cohort to identify genomic alterations associated with the disease, such as copy number variation (CNV), integrated viral sequences, and fusion genes, along with correlation with tumor stage for better disease prognosis. As such, we collected cfDNA from 30 OSCC patients and found a significantly high positive Pearson correlation (at 5% FDR) between cfDNA concentration and tumor stage, the appearance of a second malignancy and/or lesion sizes. We further observed that the time to recurrence and survival rate of OSCC patients also correlated with a high cfDNA concentration. Next, to understand the observed genomic alteration, we performed deep DNA sequencing, revealing genomic alterations previously also observed in TCGA/ICGC studies²³. Moreover, we routinely detected CNV in cfDNA loci containing the *TP53*, *TP63*, *FGFR1* and *MLH1* genes. In addition, we detected the presence of oncogenic virus contigs like HPV, HSV, simian virus (SV) and enterovirus (EV), which could explain the oncogenic progression of patients in the study cohort. In addition, we observed a novel fusion gene or “chimera”, *TRMO-TRNT1*, corresponding to a fusion of genes encoding tRNA regulators. *TRMO*, located on chr9q22, is involved in tRNA processing and methyltransferase activity, while *TRNT1*, located on chr3p26, helps in adding CCA nucleotides to tRNA. The GTEx analysis showed that both *TRMO* and *TRNT1* are highly expressed in all human tissues³¹. While *TRMO* has been identified in thyroid cancer, its association with OSCC remains to be shown³². Mutations and splicing defects in *TRNT1* have been associated with sideroblastic anemia³³. However, the role of *TRNT1* in cancer is still

unknown. Our findings may thus help to further characterize these genes and their association with cancers as well as to advance our understanding of the genomic markup of OSCC patients and the applications in the early diagnostics and survival prognostics.

Materials And Methods

Sample collection

Blood samples of 30 OSCC patients were collected in cfDNA preservation tubes at the Rabin Medical Center following Helsinki committee approval (OSCC #0813-16-RMC). Blood samples were centrifuged for 20 min at RT to separate the plasma and PBMC. The plasma samples were collected and aliquoted into Eppendorf tubes and stored in -80°C until use.

cfDNA extraction

Aliquots (1 ml) of plasma samples from 30 patients were subjected to cfDNA extraction using a Qiagen QIAamp cfDNA/RNA kit (Cat no. 55184), following the manufacturer's protocol. CfDNA was eluted in 50 µl elution buffer. Extracted cfDNA concentrations were measured by means of the Qubit dsDNA High Sensitivity assay (ThermoFisher Scientific, Waltham, MA) using a Qubit2.0 fluorometer. A Bioanalyzer 2100 DNA High Sensitivity assay was performed to determine the cfDNA fragment size distribution.

Copy number analyses

Extracted cfDNA samples from all patients were sequenced using Illumina high-throughput whole genome sequencing (at least 50 million reads per sample, NextSeq 550). Paired-end sequencing was performed. For copy number analysis, the iChorCNA and Gistic2.0 pipelines were used with the default parameters.

Chimera identification and validation

Using the *in-house* chimera detection pipeline ChiTaH³⁴, novel fusion genes were identified in sequenced cfDNA samples. To validate the ChiTaH results, primers were designed upstream and downstream of the gene-gene junction sequence of a fusion gene (See supplementary Table2) PCR was performed using Hylab Hy-Taq Ready Mix (2X) (Cat no. EZ3006/7/636) (For PCR conditions refer supplementary Table 3). PCR products were purified using a Macherey-Nagel NucleoSpin Gel and PCR Clean-up Kit (Cat no: 12303368), followed by the Sanger sequencing using MacroGen.

Identification of coding potential

The coding potential of a chimera was determined using the CPAT³⁵ and CNIT³⁶ webserver tools, by means of the default parameters.

Virus detection in cfDNA

A VirusFinder2.0 pipeline was used to identify the presence of oncogenic viruses in cfDNA samples, with the default parameters³⁷.

Gene ontology analysis

Gene ontology analyses was performed using PantherDB³⁸ software.

Statistical analysis

Statistical analysis was performed using GraphPad Prism. A Shapiro-Wilk test was used for various correlation analyses. T-test was performed to analyze the significant difference between the cfDNA concentration of healthy and OSCC patients. Survival analysis was done using a Kaplan-Meier curve, included in the Prism GraphPad software. *P-value* was considered at ≤ 0.05 for statistical significance at 5% FDR.

Results

It is known that high concentrations of cfDNA were observed in tissue injuries, cancer, and various autoimmune diseases. The demography of all 30 OSCC patients and 20 healthy individuals considered in our studies were comparable (see Supplementary Tables 1A and 1B). The cfDNA samples of OSCC and healthy individuals were extracted and subjected to BioanalyzerTM evaluations (Figure S1, Supplementary Material). Firstly, we studied the difference in cfDNA concentration of OSCC patients vs. healthy individuals and identified that cfDNA in OSCC patients were significantly higher than the cfDNA concentrations of healthy individuals (Figure 1A) (*p-value* < 0.05 , t-Test). Thereby suggesting that OSCC patients have a significantly higher cfDNA concentration than normal. Next, we sought to understand the correlation of increased cfDNA levels with various tumorigenic parameters, like tumor stage, a second malignancy, patient survival and more. In this study, cancers of oral cavity sub-sites samples were considered. These included twenty tongues, eight alveolar ridges, one floor of the mouth, and one retromolar trigone. Eleven patients showed mandibular involvement at presentation, meaning the bone of the mandible was invaded by the tumor at diagnosis, nine had undergone segmental mandibulectomy and two had experienced marginal mandibulectomy procedures. To check if increased cfDNA levels had direct correlation with tumor stage, we performed the Pearson correlation analyses. We observed that even though the average cfDNA concentrations in patients with tumor stage 3 or 4 were high, as compared to patients with tumor stages 1 and 2, the overall distributions were similar, other than a few cases with stage 3 and 4 tumors that presented very high concentrations of cfDNA in their blood samples (Figure 1B). This suggests that cfDNA concentrations above a certain threshold can indicate the presence of stage 3 or 4 OSCC tumors at 5% FDR, whereas lower levels give no indication of tumor stage. We also observed similar results with secondary vs. primary malignancies (Figure 1C). In other words, cfDNA concentrations above a certain threshold can indicate a secondary malignancy, while lower concentrations give no clear indication. High cfDNA concentration also defines the probability of disease recurrence in OSCC patients (Figure 1D). Then, using the Kaplan-Meier survival analysis method on data describing the OSCC recurrence and death vs. cfDNA concentration, we found that patients with cfDNA concentrations of 27 ng/ml and less had a higher survival probability (68%; Figures 1E and 1F). These results indicate that cfDNA concentrations above a threshold of 27 ng/ml can be used to recognize the tumor stages 3 and 4, which, furthermore, can be associated with a decreased survival. This study

thus helped in identifying the probability of survival and underline the tumor stages by means of the cfDNA concentration as a biomarker. In future, this method could be used as an even more sensitive biomarker for early cancer detection.

Oncogenic viruses were identified when analyzing cfDNA

In the present study, we detected partial contigs of HPV and other oncogenic viruses. Specifically, nine of 30 OSCC patients showed the presence of viral DNA integration into cfDNA (Figure 2A). Moreover, we observed sequences from HSV strains 1, 3 and 5, SV, HPV and EV (Figure 2B). HSV integrations were identified in six OSCC patients in our study, three patients had HSV-1 and three patients had HSV-5 integrations. The relation of EV with cancer has not been completely established, however, some evidence shows a link to malignancy in gliomas and to progression of cervical cancers. SV has been identified in the serum of lung cancer patients. However, SV and EV have not yet been recognized as causing OSCC. These results indicate that our study revealed the presence of more than two viruses in OSCC patient sera (Figures 3A and 3B). However, the status of these viruses cannot yet be statistically correlated with tumor stage in our cohort. Nonetheless, the presence of viruses may serve some oncogenic role in OSCC, and more samples should be used to identify their characteristics in the OSCC patients.

A novel chimera identified in cfDNA

Fusion genes produced by chromosomal translocations were common in lymphomas and leukemias, yet are extremely rare in HNSCC^{23,39}. Using our *in-house* chimera analysis tool ChiTaH, we identified the novel fusion *TRMO-TRNT1* in the cfDNA samples of two patients (Figure S2, Supplementary Material). TRMO (tRNA methyl-O-transferase) and TRNT1 (tRNA nucleotide transferase I) were highly expressed in all tissue types. To validate this chimera, we designed primers and performed PCR on 2 samples (Figure 3). Next, we performed PCR on the other 28 samples and observed a 108 bp fused sequence in seven samples (Figure S3, Supplementary Material). The band containing this fusion was excised from the agarose gel, purified, and assessed by Sanger sequencing, which confirmed the fusion junction of the two parental genes, *TRMO* and *TRNT1* (Figure S3, Supplementary Material). The fusion was identified in seven patients with a high abundance (more than 20 reads covering the fusion junction site) showing the tumor advanced malignancy and a proliferation status. Altered expression of *TRMO* has been observed in patients with thyroid carcinoma³², while altered *TRNT1* expression was seen in colorectal cancer patients³³. These results suggest that fusion genes could be used as biomarkers and explored in the search for additional OSCC patients who could be revealed by means of the deep sequencing of cfDNA samples. Finally, we checked the coding potential of the observed chimera to produce a functional protein. For this, we utilized three tools commonly used for analyzing the coding/non-coding potential of a given DNA sequence. The scores obtained by CPAT and CNIT programs suggested that the fusion has a <0.3% coding probability. Therefore, the fusion does not have coding potential (Figures S4A and S4B) and may serve as a biomarker of the OSCC progression by means of a highly abundant non-coding cfDNA fragment.

Copy number variation analysis of OSCC patient cfDNA

Copy Number Variation (CNV) was commonly observed in many cancers. Various studies have identified CNV and somatic mutations using cfDNA^{14,40-43}. Our aim here was to identify significant changes in copy numbers in OSCC patients using cfDNA genomic data. We performed CNV analysis on the sequenced cfDNA of OSCC patients using Gistic2.0, which assesses low pass copy number variations. The Q value was set at 0.01 for level significance. We observed significant amplifications in chromosomes 3q22.2, 7q35, and 15q26. Additional amplifications were also seen in chromosomes 8p21.3, 10q26.2, 2p25 and 1q21.3 (Figure 4A). Some of our findings correlate with TCGA HNSCC data for CNV and significantly mutated genes. Next, we performed functional enrichment analysis using PantherDB³⁸ and observed that commonly amplified genes in our study were predicted to play a significant role in GPCR pathways, opioid pathways, immune system activation pathways, apoptosis, and angiogenesis activation pathways (Figures 4B and 4C). Particularly, we identified deleterious regions in patient cfDNA samples. In our cohort, we observed that chromosomes 1q23, 2q22, 3p21, 3q26, 7q31, 8p21, 9q34, 13q13 and 14q21 had the greatest numbers of deletions (Figure 4B). Significantly mutated genes, like *TP53*, *TP63*, *FGFR1*, or *MLH1*, have been shown to present deletions in those regions and were also identified in our study^{23,44,45}. Our gene ontology (GO) analysis of amplification regions found the deleterious genes in our samples assigned the affected genes as being mostly involved in immune activation pathways, apoptosis signaling pathways, particularly, the *CCKR* gene, cell cycle pathways and various metabolic pathways (Figure 4D). These results indicate that cfDNA analyses may reveal significant CNV in the OSCC samples and may be used for the OSCC early diagnostics and its survival prognostics.

Discussion

cfDNA has been explored as a prognostic and diagnostic biomarker in many cancers^{12,16,17,19,30,46}. Correlation of cfDNA levels with various tumor parameters has been established in glioblastoma and neuroblastoma, where the concentration of cfDNA being correlated with tumor burden. High cfDNA concentrations were observed in samples with cancer, as compared to cfDNA from healthy samples^{12,47}. In our study, we observed the cfDNA concentration of OSCC patients were significantly higher than cfDNA concentration of healthy patients. This result suggests that cfDNA concentration of OSCC patients could be used for the early and late diagnostics. Then, we explored the correlation between the cfDNA concentration from 30 OSCC patients and tumor stages. High cfDNA levels were observed in patients with stage 3 and 4 tumors, while comparatively lower cfDNA concentrations were observed in patients with stage 1 and 2 tumors. We also observed a direct correlation between higher cfDNA concentration at presentation and the possibility of future recurrence and a secondary malignancy. We also observed that the threshold of maximum cfDNA concentration for prognostication was <27 ng/ml. The Kaplan-Meier survival analysis showed that probability of survival to be 68% for patients with OSCC at cfDNA concentrations above 27 ng/ml. Therefore, our study suggests that cfDNA could be used as a non-invasive method to detect OSCC at an early stage. Still, the analysis of more samples could have resulted in a better level of significance for the correlation between the cfDNA concentration and the tumor parameters.

We have also addressed various genomic alterations in the cfDNA of OSCC patients. One such alteration was observed as the presence of viral DNA integrations. Deep sequencing of the cfDNA of OSCC patients revealed presence of HPV, SV, HSV and EV integrations. While a high proportion of patients (48%) did not show the presence of any virus, a few patients presented more than one virus. Interestingly, HPV has been studied as a cause of HNSCC, cervical cancer and other gynecological and urological cancers^{4,14,20,48,49}. We identified HPV in six out of 30 samples. HSV strains 1 and 5 were identified in six of 30 samples. HSV was previously reported in samples from HNSCC and OSCC patients and its association with the progression of cancer was claimed⁵⁰⁻⁵². Enterovirus has been associated with malignant glioma⁵³. SV was reported in samples of osteosarcoma and prostate cancer⁵⁴⁻⁵⁶. However, these viruses have not yet been associated with OSCC. Future studies could establish the association of these viruses with OSCC and determine if they are involved in oncogenic progression.

Using the *in-house* ChiTaH pipeline³⁴, we identified the novel fusion *TRMO-TRNT1*. PCR and Sanger sequencing validated the presence of this fusion in seven samples from patients with late-stage tumors. Mutation in *TRMO* has been associated with thyroid carcinoma³². *TRNT1* has not been associated with any cancer thus far, although its mutation is responsible for causing congenital disease and sideroblastic anemia³³. The fusion product does not have any coding potential, according to CPAT³⁵ and CNIT³⁶. In future, it might be interesting to explore the mechanism of action of this fusion gene in OSCC progression.

Finally, CNV was considered. CNV in tissues, as well as in cfDNA, has been studied and was shown to be associated with many cancers, including OSCC.⁴⁰ In our study, we found regions of chromosomes 3q22.2, 7q35, and 15q26 to be amplified. Amplifications were also seen in chromosomes 8p21.3, 10q26.2, 2p25 and 1q21.3. Gene Ontology pathway analysis of genes at

these loci revealed them to be associated with angiogenesis, immune activation pathways, and GPCR, interleukin, VEGF, FGF, vasopressin activation pathways. The deleterious regions at chromosomes 1q23, 2q22, 3p21, 3q26, 7q31, 8p21, 9q34, 13q13 and 14q21 affect genes associated with apoptosis, *CCKR*, cell cycle, and immune activation and cell signaling pathways. Mutations in these genes and structural variations associated with these loci have been studied in TCGA and by other groups. Our study agrees with TCGA and previous studies^{23,45,57,58}. In future, targeted sequencing of these genes or CNV analysis of these chromosomal loci could be used as biomarkers for OSCC.

Figure legends:

Fig. 1: Correlation of cfDNA concentration with different tumor profiles. A. cfDNA concentration of healthy vs OSCC patients ($p\text{-value} \leq 0.05$) using t-test. B. cfDNA concentration compared with tumor stage using Shapiro-Wilk normality. C. cfDNA vs. secondary malignancy. D. cfDNA vs. recurrence. E. Probability of survival was determined using a survival curve, with the threshold of survival being 27 ng/ml. F. Survival analysis using the Kaplan-Meyer method showed 68% probability of survival within the cohort.

Fig. 2: Identification of viral DNA in cfDNA samples. A. Pie chart showing the percentage of samples containing viral DNA. B. Presence of different viral DNA in the samples. Some patients had DNA from more than one virus in their sample.

Fig. 3: Identification of a novel fusion. A. Agarose gel of PCR products from two confirmed patient samples with the fusion highlighted by a red box.

Fig. 4: Copy number variation analyses of cfDNA sequences: CNV analysis was done on 30 patient cfDNA samples using Gistic2.0. An amplification plot suggests (A) amplification in the regions 8p21.3, 10q26.2, 2p25 and 1q21.3 and (B) deletions in chromosomes 1q23, 2q22, 3p21, 3q26, 7q31, 8p21, 9q34, 13q13 and 14q21. C,D. Gene ontology analysis of amplified (C) and deleted regions (D) using PantherDB. Genes related to various signaling pathways and the apoptosis pathway were enriched.

Figures

Fig 1A




Fig 1B




Fig 1C




Fig 1D




Fig 1E




Fig 1F




Fig 2A





Fig 2B






Fig 4A





Fig 4B



References:

1. Sinevici, N. & O'sullivan, J. Oral cancer: Deregulated molecular events and their use as biomarkers. *Oral Oncol* **61**, 12–18 (2016).
2. Montero, P. H. & Patel, S. G. Cancer of the Oral Cavity. *Surgical Oncology Clinics of North America* vol. 24 491–508 Preprint at <https://doi.org/10.1016/j.soc.2015.03.006> (2015).
3. Inchingolo, F. *et al.* Oral cancer: A historical review. *International Journal of Environmental Research and Public Health* vol. 17 Preprint at <https://doi.org/10.3390/ijerph17093168> (2020).
4. Katirachi, S. K., Grønlund, M. P., Jakobsen, K. K., Grønhøj, C. & von Buchwald, C. The Prevalence of HPV in Oral Cavity Squamous Cell Carcinoma. *Viruses* vol. 15 Preprint at <https://doi.org/10.3390/v15020451> (2023).
5. Hernandez, B. Y. *et al.* Human papillomavirus DNA detection, p16 INK4a, and oral cavity cancer in a U.S. population. *Oral Oncol* **91**, 92–96 (2019).
6. *Oral Human Papilloma Virus Infection: An Overview of Clinical-Laboratory Diagnosis and Treatment*.
7. Nakagaki, T. *et al.* Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma. *Tumor Biology* **40**, (2018).
8. Lousada-Fernandez, F. *et al.* Liquid Biopsy in Oral Cancer. *Int J Mol Sci* **19**, 1704 (2018).
9. Sumanasuriya, S., Lambros, M. B. & de Bono, J. S. Application of Liquid Biopsies in Cancer Targeted Therapy. *Clin Pharmacol Ther* **102**, 745–747 (2017).
10. Kang, Z., Stevanovic, S., Hinrichs, C. S. & Cao, L. Circulating cell-free DNA for metastatic cervical cancer detection, genotyping, and monitoring. *Clinical Cancer Research* **23**, 6856–6862 (2017).
11. Cordeiro Mitchell, C. N., Murdock, T., Fader, A. N. & Stone, R. L. Advanced ovarian cancer treated in pregnancy and detected by cell-free DNA aneuploidy screening. *Gynecol Oncol Rep* **24**, 48–50 (2018).
12. Wang, X. *et al.* Plasma cell-free DNA quantification is highly correlated to tumor burden in children with neuroblastoma. *Cancer Med* **7**, 3022–3030 (2018).
13. Fawzy, A., Sweify, K. M., El-Fayoumy, H. M. & Nofal, N. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence. *J Egypt Natl Canc Inst* **28**, 235–242 (2016).
14. Wang, Y. *et al.* Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. *Sci Transl Med* **7**, (2015).
15. Grisanti, S. *et al.* Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: Prognostic and predictive significance. *PLoS One* **9**, (2014).
16. Krebs, M. G. *et al.* Molecular analysis of circulating tumour cells - Biology and biomarkers. *Nat Rev Clin Oncol* **11**, 129–144 (2014).
17. Di Meo, A., Bartlett, J., Cheng, Y., Pasic, M. D. & Yousef, G. M. Liquid biopsy: A step forward towards precision medicine in urologic malignancies. *Mol Cancer* **16**, (2017).
18. Yu, M., Stott, S., Toner, M., Maheswaran, S. & Haber, D. A. Circulating tumor cells: Approaches to isolation and characterization. *Journal of Cell Biology* **192**, 373–382 (2011).
19. Alpaugh, R. K., Zhou, L. L., Dicker, D. T., Matthew, E. & El-Deiry, W. S. Circulating tumor cells: Silent predictors of metastasis. *F1000Res* **6**, (2017).

20. Mazurek, A. M., Rutkowski, T., Fiszer-Kierzkowska, A., Małusecka, E. & Składowski, K. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. *Oral Oncol* **54**, 36–41 (2016).
21. Xiao, X. *et al.* Advances in the oral microbiota and rapid detection of oral infectious diseases. *Frontiers in Microbiology* vol. 14 Preprint at <https://doi.org/10.3389/fmicb.2023.1121737> (2023).
22. Bodelon, C., Untereiner, M. E., Machiela, M. J., Vinokurova, S. & Wentzensen, N. Genomic characterization of viral integration sites in HPV-related cancers. *Int J Cancer* **139**, 2001–2011 (2016).
23. Lawrence, M. S. *et al.* Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* **517**, 576–582 (2015).
24. Morgan, I. M., Dinardo, L. J. & Windle, B. Integration of human papillomavirus genomes in head and neck cancer: Is it time to consider a paradigm shift? *Viruses* **9**, (2017).
25. Saproo, S. *et al.* Salivary protein kinase C alpha and novel microRNAs as diagnostic and therapeutic resistance markers for oral squamous cell carcinoma in Indian cohorts. *Front Mol Biosci* **9**, (2023).
26. Arantes, L. M. R. B., De Carvalho, A. C., Melendez, M. E. & Carvalho, A. L. Serum, plasma and saliva biomarkers for head and neck cancer. *Expert Review of Molecular Diagnostics* vol. 18 85–112 Preprint at <https://doi.org/10.1080/14737159.2017.1404906> (2017).
27. Lin, L. H., Chang, K. W., Kao, S. Y., Cheng, H. W. & Liu, C. J. Increased plasma circulating cell-free DNA could be a potential marker for oral cancer. *Int J Mol Sci* **19**, (2018).
28. Chattopadhyay, I., Verma, M. & Panda, M. Role of Oral Microbiome Signatures in Diagnosis and Prognosis of Oral Cancer. *Technol Cancer Res Treat* **18**, (2019).
29. Patel, S., Shah, K., Mirza, S., Shah, K. & Rawal, R. Circulating tumor stem like cells in oral squamous cell carcinoma: An unresolved paradox. *Oral Oncol* **62**, 139–146 (2016).
30. Hamana, K. *et al.* Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. *Br J Cancer* **92**, 2181–2184 (2005).
31. Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580 (2013).
32. Kulkarni, O. *et al.* Gene network and biological pathways associated with susceptibility to differentiated thyroid carcinoma. *Sci Rep* **11**, 8932 (2021).
33. Wedatilake, Y. *et al.* TRNT1 deficiency: clinical, biochemical and molecular genetic features. *Orphanet J Rare Dis* **11**, (2016).
34. Detroja, R., Gorohovski, A., Giwa, O., Baum, G. & Frenkel-Morgenstern, M. ChiTaH: a fast and accurate tool for identifying known human chimeric sequences from high-throughput sequencing data. *NAR Genom Bioinform* **3**, (2021).
35. Wang, L. *et al.* CPAT: Coding-potential assessment tool using an alignment-free logistic regression model. *Nucleic Acids Res* **41**, (2013).
36. Guo, J. C. *et al.* CNIT: a fast and accurate web tool for identifying protein-coding and long non-coding transcripts based on intrinsic sequence composition. *Nucleic Acids Res* **47**, W516–W522 (2019).
37. Wang, Q., Jia, P. & Zhao, Z. VirusFinder: software for efficient and accurate detection of viruses and their integration sites in host genomes through next generation sequencing data. *PLoS One* **8**, (2013).

38. Mi, H. *et al.* PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API. *Nucleic Acids Res* **49**, D394–D403 (2021).
39. Stransky, N. *et al.* The mutational landscape of head and neck squamous cell carcinoma. *Science (1979)* **333**, 1157–1160 (2011).
40. Shlien, A. & Malkin, D. Copy number variations and cancer. *Genome Medicine* vol. 1 Preprint at <https://doi.org/10.1186/gm62> (2009).
41. Zhang, N., Wang, M., Zhang, P. & Huang, T. Classification of cancers based on copy number variation landscapes. *Biochim Biophys Acta Gen Subj* **1860**, 2750–2755 (2016).
42. Tan, E. S. *et al.* Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer. *Cancers (Basel)* **14**, (2022).
43. Palande, V. *et al.* Detection of Point Mutations and Gene Fusions from Circulating Cell-Free DNA of Glioma Patients.
44. Wang, C.-I. *et al.* Characterization of Copy Number Variations in Oral Cavity Squamous Cell Carcinoma Reveals a Novel Role for MLLT3 in Cell Invasiveness. *Oncologist* **24**, e1388–e1400 (2019).
45. Rhie, A. *et al.* Genomic copy number variations characterize the prognosis of both P16-positive and P16-negative oropharyngeal squamous cell carcinoma after curative resection. *Medicine (United States)* **94**, (2015).
46. Perdomo, S. *et al.* Circulating tumor DNA detection in head and neck cancer: Evaluation of two different detection approaches. *Oncotarget* **8**, 72621–72632 (2017).
47. Palande, V. *et al.* Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis. *Mol Oncol* **16**, 2098 (2022).
48. Sastre-Garau, X. *et al.* A NGS-based blood test for the diagnosis of invasive HPV-associated carcinomas with extensive viral genomic characterization. *Clinical Cancer Research* **27**, 5307–5316 (2021).
49. Costa, R. L., Boroni, M. & Soares, M. A. Distinct co-expression networks using multi-omic data reveal novel interventional targets in HPV-positive and negative head-and-neck squamous cell cancer. *Sci Rep* **8**, (2018).
50. Brown, S. H., States, V. A. R., Afghan, A. K. & Satyanarayana, G. Herpes simplex virus-infected squamous cell carcinoma: a case report. *BMC Infect Dis* **22**, (2022).
51. Mosmann, J. P. *et al.* Sexually transmitted infections in oral cavity lesions: Human papillomavirus, Chlamydia trachomatis, and Herpes simplex virus. *J Oral Microbiol* **11**, (2019).
52. Wołańciewicz, M., Becht, R., Grywalska, E. & Niedźwiedzka-Rystwej, P. Herpesviruses in head and neck cancers. *Viruses* **12**, (2020).
53. Zhang, X. *et al.* Enterovirus A71 Oncolysis of Malignant Gliomas. *Molecular Therapy* **28**, 1533–1546 (2020).
54. Mazzoni, E. *et al.* Significant association between human osteosarcoma and Simian virus 40. *Cancer* **121**, 708–715 (2015).
55. Shah, K. V., Galloway, D. A., Knowles, W. A. & Viscidi, R. P. Simian virus 40 (SV40) and human cancer: a review of the serological data. *Rev Med Virol* **14**, 231–239 (2004).

56. Shah, K. V., Weismann, M. & Murphy, G. P. Occurrence of simian virus 40 (SV40)-reacting antibodies in sera of some patients with prostatic cancer. *J Surg Oncol* **4**, 89–93 (1972).
57. Wu, F., Du, Y., Hou, X. & Cheng, W. A prognostic model for oral squamous cell carcinoma using 7 genes related to tumor mutational burden. *BMC Oral Health* **22**, (2022).
58. Wang, C.-I. *et al.* Characterization of Copy Number Variations in Oral Cavity Squamous Cell Carcinoma Reveals a Novel Role for MLLT3 in Cell Invasiveness. *Oncologist* **24**, e1388–e1400 (2019).